Results 301 to 310 of about 138,770 (367)

Hijacking erythropoietin: A tumour‐intrinsic strategy to escape immune surveillance

open access: yes
Clinical and Translational Medicine, Volume 15, Issue 8, August 2025.
David Kung‐Chun Chiu, Edgar G Engleman
wiley   +1 more source

The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP‐1 Agonists: A Literature Review

open access: yesJournal of Diabetes, Volume 17, Issue 8, August 2025.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated substantial weight loss effects among patients with diabetes and obesity. However, given the rapid weight loss induced, there is concern about the total change in body composition, including lean body mass (LBM).
Jimmy Wen   +8 more
wiley   +1 more source

CDK-driven phosphorylation of TRAIP is essential for mitotic replisome disassembly and MiDAS. [PDF]

open access: yesNucleic Acids Res
Poovathumkadavil D   +8 more
europepmc   +1 more source

The Life of a Kidney Podocyte

open access: yesActa Physiologica, Volume 241, Issue 8, August 2025.
ABSTRACT Aim Podocytes, highly specialized epithelial cells located in the glomerulus of the kidney, are essential to the filtration barrier that ensures separation of blood and urine. These cells exhibit a unique architecture, characterized by an intricate network of foot processes interconnected by slit diaphragms, which serve as a critical selective
Desiree Loreth   +2 more
wiley   +1 more source

Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications. [PDF]

open access: yesResearch (Wash D C)
Baldi S   +8 more
europepmc   +1 more source

CDK13‐Related Disorder: Novel Insights From A Series of 27 Cases and Recommendations for Clinical Management

open access: yesClinical Genetics, Volume 108, Issue 2, Page 146-155, August 2025.
This report described 27 novel subject with CDK13‐related disorders. Collecting the clinical and radiological data, we better define the phenotypic spectrum of this condition and we suggest a comprehensive clinical management. ABSTRACT In 2016, Sifrim and colleagues described the first group of patients carrying heterozygous pathogenic variants in ...
Gianluca Contrò   +57 more
wiley   +1 more source

ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma

open access: yesThe FEBS Journal, Volume 292, Issue 15, Page 3986-4005, August 2025.
KRAB zinc finger protein ZNF224 acts as an oncogenic factor in melanoma cells, enhancing p21 cytosolic retention and impairing nuclear p21 cytostatic activity through stimulation of the AKT pathway. Furthermore, ZNF224 regulates transcriptional expression levels of p21 via p53.
Leandra Sepe   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy